Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
NCT00105313 · MedImmune LLC · PHASE1 · terminated · last registry update 2007-06-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “After review of safety events and have decided that further dose escalation of MEDI-507 as a single agent is not feasible.” | – | Registry record, MedImmune LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2008-06-06Phase 3 first posted: Astellas Pharma Inc, Alefacept (NCT00692172)
- 2008-05-07Phase 3 first posted: Astellas Pharma Inc, alefacept (NCT00674063)
- 2008-05-07Phase 3 first posted: Astellas Pharma Inc, alefacept + placebo (NCT00673556)
- 2007-06-14Also stopped (terminated): MedImmune LLC, MEDI-507 (NCT00123942)
- 2006-08-08Phase 3 first posted: Hadassah Medical Organization, Alefacept (AMEVIVE®) + control group (NCT00361413)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision